 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
 |
Research / Antithrombin Clinical Trial
Patients with hereditary antithrombin deficiency have low circulating levels of antithrombin (AT), a naturally
occurring blood protein that is the principle inhibitor of coagulation. Individuals with hereditary AT deficiency either do not produce enough of this
protein, or what they produce does not function properly. They have a significantly increased risk for venous thrombosis and pulmonary embolism, particularly
during high risk events such as childbirth and surgery.
Using genetic engineering, GTC Biotherapeutics has developed a recombinant form of antithrombin (ATryn®). All forms of antithrombin today are derived
from pooled human plasma. The company finished one clinical trial and in August 2006, the European Authorities approved ATryn® for the prophylaxis
of venous thromboembolism in surgery of patients with hereditary antithrombin deficiency. GTC has initiated a new international clinical trial, and they
are again evaluating recombinant AT in patients with hereditary AT deficiency.
If you or a family member would like to learn more about this new study, including how to participate, please ask your physician or health care provider
to visit www.clinicaltrials.gov, key words, recombinant antithrombin, to see a description of the trial. Your
caregiver may also wish to contact GTC clinical staff directly to receive more information.